share_log

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $93

Barrington Research Maintains Outperform on LeMaitre Vascular, Raises Price Target to $93

Barrington研究認爲勒梅特微管醫療值得買入,將目標股價上調至93美元
Benzinga ·  11/01 11:31  · 評級/大行評級

Barrington Research analyst Michael Petusky maintains LeMaitre Vascular (NASDAQ:LMAT) with a Outperform and raises the price target from $92 to $93.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論